Elusive Target of Angiogenesis in Small-Cell Lung Cancer

被引：5
作者：
Neal, Joel W. [1 ]
Wakelee, Heather A. [1 ]
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 12期
关键词：
RANDOMIZED PHASE-II; DOUBLE-BLIND; BEVACIZUMAB; CHEMOTHERAPY; PLACEBO; COMBINATION; CISPLATIN; THERAPY; MULTICENTER; CARBOPLATIN;
D O I：
10.1200/JCO.2016.71.6084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1269 / +
页数：4
相关论文
共 24 条
  • [1] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
    Antonia, Scott J.
    Lopez-Martin, Jose A.
    Bendell, Johanna
    Ott, Patrick A.
    Taylor, Matthew
    Eder, Joseph Paul
    Jaeger, Dirk
    Pietanza, M. Catherine
    Le, Dung T.
    de Braud, Filippo
    Morse, Michael A.
    Ascierto, Paolo A.
    Horn, Leora
    Amin, Asim
    Pillai, Rathi N.
    Evans, Jeffry
    Chau, Ian
    Bono, Petri
    Atmaca, Akin
    Sharma, Padmanee
    Harbison, Christopher T.
    Lin, Chen-Sheng
    Christensen, Olaf
    Calvo, Emiliano
    [J]. LANCET ONCOLOGY, 2016, 17 (07) : 883 - 895
  • [2] Arnold AM, 2007, J CLIN ONCOL, V25, P4278, DOI 10.1200/JCO.2007.12.3083
  • [3] Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
    Bunn, Paul A., Jr.
    Minna, John D.
    Augustyn, Alexander
    Gazdar, Adi F.
    Ouadah, Youcef
    Krasnow, Mark A.
    Berns, Anton
    Brambilla, Elisabeth
    Rekhtman, Natasha
    Massion, Pierre P.
    Niederst, Matthew
    Peifer, Martin
    Yokota, Jun
    Govindan, Ramaswamy
    Poirier, John T.
    Byers, Lauren A.
    Wynes, Murry W.
    McFadden, David G.
    MacPherson, David
    Hann, Christine L.
    Farago, Anna F.
    Dive, Caroline
    Teicher, Beverly A.
    Peacock, Craig D.
    Johnson, Jane E.
    Cobb, Melanie H.
    Wendel, Hans -Guido
    Spigel, David
    Sage, Julien
    Yang, Ping
    Pietanza, M. Catherine
    Krug, Lee M.
    Heymach, John
    Ujhazy, Peter
    Zhou, Caicun
    Goto, Koichi
    Dowlati, Afshin
    Christensen, Camilla Laulund
    Park, Keunchil
    Einhorn, Lawrence H.
    Edelman, Martin J.
    Giaccone, Giuseppe
    Gerber, David E.
    Salgia, Ravi
    Owonikoko, Taofeek
    Malik, Shakun
    Karachaliou, Niki
    Gandara, David R.
    Slotman, Ben J.
    Blackhall, Fiona
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : 453 - 474
  • [4] A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors
    Callahan, Margaret K.
    Ott, Patrick Alexander
    Odunsi, Kunle
    Bertolini, Staphane V.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Karakunnel, Joyson Joseph
    Hodi, F. Stephen
    Wolchok, Jedd D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Targeting VEGF in lung cancer
    Das, Millie
    Wakelee, Heather
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (04) : 395 - 406
  • [6] Opinion - Angiogenesis: an organizing principle for drug discovery?
    Folkman, Judah
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (04) : 273 - 286
  • [7] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
    Garon, Edward B.
    Ciuleanu, Tudor-Eliade
    Arrieta, Oscar
    Prabhash, Kumar
    Syrigos, Konstantinos N.
    Goksel, Tuncay
    Park, Keunchil
    Gorbunova, Vera
    Dario Kowalyszyn, Ruben
    Pikiel, Joanna
    Czyzewicz, Grzegorz
    Orlov, Sergey V.
    Lewanski, Conrad R.
    Thomas, Michael
    Bidoli, Paolo
    Dakhil, Shaker
    Gans, Steven
    Kim, Joo-Hang
    Grigorescu, Alexandru
    Karaseva, Nina
    Reck, Martin
    Cappuzzo, Federico
    Alexandris, Ekaterine
    Sashegyi, Andreas
    Yurasov, Sergey
    Perol, Maurice
    [J]. LANCET, 2014, 384 (9944) : 665 - 673
  • [8] Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
    Grothey, Axel
    Sugrue, Mary M.
    Purdie, David M.
    Dong, Wei
    Sargent, Daniel
    Hedrick, Eric
    Kozloff, Mark
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5326 - 5334
  • [9] Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501
    Horn, Leora
    Dahlberg, Suzanne E.
    Sandler, Alan B.
    Dowlati, Afshin
    Moore, Dennis F.
    Murren, John R.
    Schiller, Joan H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 6006 - 6011
  • [10] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H
    Fehrenbacher, L
    Novotny, W
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Baron, A
    Griffing, S
    Holmgren, E
    Ferrara, N
    Fyfe, G
    Rogers, B
    Ross, R
    Kabbinavar, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2335 - 2342
123